Systemic Disease Distribution
Systemic Disease Distribution - Related Videos
06:51
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
0 Views •
Cited by 9 •
2018
Here we describe the delivery of microRNA using a recombinant adeno-associated virus serotype 9 in a mouse model of a neuromuscular disease. A single peripheral administration in mice resulted in sustained miRNA overexpression in muscle and motor neurons, providing an opportunity to study miRNA function and therapeutic potential in vivo.
11:51
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
0 Views •
Cited by 42 •
2010
Thorough preclinical testing of drugs that act in the central nervous system often involves assessing and comparing drug biodistribution in association with specific routes of administration. Here, three commonly used methods of systemic delivery (intravenous, intraperitoneal, and oral) as well as a method for local delivery (convection-enhanced delivery) are demonstrated in mice.
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
0 Views •
Cited by 16 •
2020
Here, we present practical recommendations for performing thoracic high-resolution computed tomography for diagnosing and assessing systemic sclerosis-related interstitial lung disease.
08:47
Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
0 Views •
Cited by 36 •
2016
This manuscript describes the methods for induction and scoring of the experimental autoimmune encephalomyelitis (EAE) model, together with the assessment of immune cell distribution and mRNA cytokine levels in lymph nodes, spleen, blood and spinal cord using flow cytometry and quantitative PCR, respectively, at various disease phases.
01:19
F Distribution
0 Views •
2023
The F distribution was named after Sir Ronald Fisher, an English statistician. The F statistic is a ratio (a fraction) with two sets of degrees of freedom; one for the numerator and one for the denominator. The F distribution is derived from the Student's t distribution. The values of the F distribution are squares of the corresponding values of the t distribution. One-Way ANOVA expands the t test for comparing more than two groups. The scope of that derivation is beyond the level of this...
FAQs
The extent and pattern of disease depend on how widely a pathogenic agent, inflammatory mediator, abnormal immune response, or malignant cell can travel. Blood flow and lymphatic connections provide routes, while tissue barriers restrict access. Receptor expression and differences in organ susceptibility further determine where disease-related effects become concentrated or clinically apparent.
These pathways provide distinct ways for disease-related material to move beyond its initial site. The bloodstream can connect distant organs, the lymphatic system links tissues through lymphatic channels, and connected tissues may permit local extension. Considering the likely route helps clinicians relate a distribution pattern to the underlying pathological process.
Organs do not respond identically to circulating agents or immune activity. Differences in tissue barriers, receptor expression, and intrinsic susceptibility can make some sites more affected than others. Consequently, a systemic process may produce an uneven clinical pattern, with symptoms or pathological changes that reflect the organs most responsive or accessible to the disease mechanism.
Clinicians can compare symptoms across organs and body systems with the suspected distribution of underlying pathology. This approach helps determine whether findings represent related effects of one broader process rather than isolated local problems. The resulting pattern can support selection of diagnostic tests designed to evaluate disease beyond the most obvious symptomatic site.
Evaluation should account for the possibility that clinically important involvement extends beyond the initially affected tissue. Clinicians use the observed pattern of symptoms and suspected pathology to choose tests that assess relevant organs, tissues, or body systems. This broader perspective reduces the risk of interpreting findings as confined to one local site.
A whole-body strategy becomes relevant when the disease process affects multiple organs, tissues, or systems rather than a single accessible site. Treatment planning must therefore address the broader distribution and the underlying cause, whether infection, immune dysregulation, metabolic abnormality, or malignancy. This perspective supports management aimed at the disease throughout the body.
The extent and pattern of involvement provide information about how broadly a disorder affects the body, which can contribute to prognosis. Repeated assessment of affected organs, tissues, or systems also helps clinicians monitor whether treatment is changing the disease pattern. These observations can support evaluation of response rather than relying on one local finding alone.